Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, explains the importance of up-to-date data when implementing medication therapy management programs.
Obtaining timely data and encouraging patient engagement are crucial to successful medication therapy management programs, said Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare.
Transcript
Are different demographics more susceptible to the effects of cytochrome P450 (CYP450) enzymes?
So everybody is different and everybody can have a different response to medications based on their genetic differences. So race and ethnicity can play a role in adverse drug events. You know, some people may be ultra metabolizers. Some may be poor metabolizers. And ultimately that's going to affect the way that they process those medications.
If medication therapy management (MTM) programs help with these issues, what are some of the barriers payers face in implementing these programs?
I think some of the biggest barriers to implementing real successful MTM programs are timely data. So you want to make sure that when you're speaking to a patient that you have the most up to date information for that patient that allows you to have more impactful interventions or recommendations with that patient, but also patient engagement. So one, how can you get ahold of this patient to talk to them about their medications and establishing that trust with the patient, that you are a clinician calling on their behalf and that you do want to help them? Make sure that they are on the most safe medications and really getting optimal use from the medications that they're taking.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More